MR
Therapeutic Areas
Tango Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| TNG908 | MTAP-deleted solid tumors (e.g., NSCLC, pancreatic cancer, glioblastoma) | Phase 1/2 |
| TNG462 | MTAP-deleted solid tumors | Phase 1/2 |
| TNG348 | BRCA1/2-mutant and other HRD+ tumors | Phase 1 |
| TNG260 | STK11-mutant cancers (e.g., NSCLC) | Phase 1/2 |
| PRMT5 Inhibitor (Undisclosed) | Undisclosed genetically defined cancers | Preclinical |
| USP1 Inhibitor (Undisclosed) | BRCA1/2-mutant and other HRD+ tumors | Preclinical |
Leadership Team at Tango Therapeutics
BW
Barbara Weber, M.D.
President, Chief Executive Officer, and Director
AC
Adam Crystal, M.D., Ph.D.
Chief Medical Officer
JV
John V. Gray, Ph.D.
Chief Scientific Officer
MC
Michele Cleary, Ph.D.
Chief Technology Officer
RK
Rebecca Kusko, Ph.D.
Chief Development Officer
AH
Alan Huang, Ph.D.
Chief Platform Officer
EC
Ellen Chiniara, J.D.
Chief Legal Officer and Corporate Secretary
AM
Adam M. Koppel, M.D., Ph.D.
Chairman of the Board of Directors
KF
Keith Flaherty, M.D.
Director
CB
Cynthia Butitta
Director